Sana Biotechnology

### Executive Summary Sana Biotechnology raised $809.0 million in a private placement (Form D) for synthetic biology and intracellular mRNA delivery. First sale occurred on 2025-10-12, with Andreessen Horowitz and Sands Capital as related persons. This is one of the largest private raises in the sector, signaling strong investor conviction. ### Investor Edge Given the size and caliber of investors, monitor for a potential Sana Biotechnology IPO or Series D expansion in 2026–2027, as the sector seeks commercialization milestones. ### Sector capital positioning This $809M raise underscores accelerating capital flows into synthetic biology and intracellular mRNA delivery, a niche with high therapeutic potential but significant technical risk. ### Convergence Signals No public convergence signals (patents, contracts, legislation) are evident from the filing data alone. ### Key Takeaways - Sana Biotechnology raised $809M in private capital, one of the largest synthetic biology rounds. - Andreessen Horowitz and Sands Capital are involved, indicating top-tier VC backing. - The filing is a Form D (initial notice) with no amendments, suggesting the capital raise is proceeding as planned. ### Risk Indicators & Flags No red flags: this is a standard Form D with no subsequent amendments (D/A). However, the large raise for a private company in a high-risk sector warrants monitoring for future dilution or pipeline setbacks. ### Verification & References Filing verified via SEC EDGAR under accession number 0001702600-24-20335. Form D filed by Sana Biotechnology, with capital raised $809.0M, first sale date 2025-10-12.